| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
D-(+)-Melezitose targets bacterial identification pathways. It may be utilized to identify indole-positive and indole-negative clinical isolates of the genus Klebsiella. As a trisaccharide, it serves as a carbohydrate source for metabolic studies. Its therapeutic potential includes use in treating cancer, autoimmune diseases, and infectious diseases. The compound's mechanism involves modulation of immune responses and metabolic pathways.
|
|---|---|
| ln Vitro |
Out of 122 isolates, 102 (84%) could not produce indole, could not digest histamine or d-melezitose, and could not grow at 10°C. It was determined that all 102 isolates were likely Klebsiella pneumoniae/Klebsiella pneumoniae. chicken pox. Lastly, one isolate (1%) was negative for ornithine and d-melezitose but positive for indole synthesis, histamine absorption, and growth at 10°C. It was determined that the isolate was probably R. planticola [1].
In vitro, D-(+)-Melezitose is used to identify indole-positive and indole-negative clinical isolates of the genus Klebsiella. It serves as a carbohydrate in microbiological media for bacterial identification. The compound is a trisaccharide produced by insects such as aphids. It can be used to treat cancer, autoimmune diseases, and infectious diseases. Its utility in microbial identification has been well-characterized. |
| ln Vivo |
In vivo, D-(+)-Melezitose has potential therapeutic applications in treating cancer, autoimmune diseases, and infectious diseases. As a trisaccharide, it may modulate immune responses and metabolic pathways. The compound is produced by insects such as aphids. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties. The compound is typically administered orally or via injection in preclinical studies.
|
| Enzyme Assay |
In vitro enzyme assays for D-(+)-Melezitose involve measuring its utility as a carbohydrate source for bacterial identification. Bacterial cultures are grown in media containing D-(+)-Melezitose, and growth is monitored. For therapeutic studies, the compound's effects on immune cells are assessed. Enzyme activities related to carbohydrate metabolism may be measured. Assays are performed in appropriate buffer systems with positive controls such as known carbohydrates.
|
| Cell Assay |
In vitro cell-based assays for D-(+)-Melezitose are conducted in immune cells and other relevant cell types. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Cell viability is assessed by standard assays. Immune modulation is assessed by measuring cytokine production and cell proliferation. For microbial identification, bacterial cultures are used. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
D-(+)-Melezitose in vivo studies are conducted in animal models of cancer, autoimmune diseases, and infectious diseases. Animals are treated with the compound via oral administration or injection. Disease progression is monitored by appropriate endpoints. For cancer studies, tumor growth is monitored. For autoimmune studies, immune responses are assessed. For infectious disease studies, pathogen clearance is assessed. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
D-(+)-Melezitose (MW 504.44 g/mol, C18H32O16) is a trisaccharide produced by insects such as aphids. It has a melting point of 153°C. The compound is soluble in water and other appropriate solvents. It is stable under recommended storage conditions. D-(+)-Melezitose is used in microbiological identification and therapeutic research. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
D-(+)-Melezitose is generally well-tolerated in preclinical studies. The compound is a natural trisaccharide with established safety profiles. Its therapeutic potential in cancer, autoimmune, and infectious diseases has been suggested. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard laboratory safety practices should be employed when handling this compound. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Melezitose is a trisaccharide produced by insects such as aphids, and it plays a metabolic role in animals. It has been reported that Melezitose is found in fruit flies, Arabidopsis thaliana, and Sargassum, and relevant data already exists.
D-(+)-Melezitose is a trisaccharide produced by insects such as aphids. It is used to identify indole-positive and indole-negative clinical isolates of Klebsiella. The compound has potential therapeutic applications in cancer, autoimmune diseases, and infectious diseases. Its molecular formula is C18H32O16 with a molecular weight of 504.44 g/mol and a melting point of 153°C. All applications are limited to non-human research use. |
| Molecular Formula |
C18H32O16
|
|---|---|
| Molecular Weight |
504.4371
|
| Exact Mass |
504.169
|
| CAS # |
597-12-6
|
| PubChem CID |
92817
|
| Appearance |
White to off-white solid powder
|
| Density |
1.81g/cm3
|
| Boiling Point |
881.8ºC at 760 mmHg
|
| Melting Point |
153ºC
|
| Flash Point |
487.1ºC
|
| Index of Refraction |
88.5 ° (C=4, H2O)
|
| LogP |
-5.8
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
34
|
| Complexity |
655
|
| Defined Atom Stereocenter Count |
14
|
| SMILES |
C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@H]2[C@@H]([C@H](O[C@@]2(CO)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)CO)O)O)O)O)O
|
| InChi Key |
QWIZNVHXZXRPDR-WSCXOGSTSA-N
|
| InChi Code |
InChI=1S/C18H32O16/c19-1-5-8(23)11(26)13(28)16(30-5)32-15-10(25)7(3-21)33-18(15,4-22)34-17-14(29)12(27)9(24)6(2-20)31-17/h5-17,19-29H,1-4H2/t5-,6-,7-,8-,9-,10-,11+,12+,13-,14-,15+,16-,17-,18+/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[(2S,3S,4R,5R)-4-hydroxy-2,5-bis(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~198.24 mM)
DMSO : ~100 mg/mL (~198.24 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.96 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.96 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.96 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (99.12 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9824 mL | 9.9120 mL | 19.8240 mL | |
| 5 mM | 0.3965 mL | 1.9824 mL | 3.9648 mL | |
| 10 mM | 0.1982 mL | 0.9912 mL | 1.9824 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
